{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T19:06:01Z","timestamp":1769281561714,"version":"3.49.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA050723"],"award-info":[{"award-number":["R25DA050723"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA047296"],"award-info":[{"award-number":["DA047296"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"Semel Charitable Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1038\/s41386-023-01538-y","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T20:03:32Z","timestamp":1675281812000},"page":"850-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Controlled human drug administration studies are necessary to define the THC-sparing effects of CBD and other cannabis constituents"],"prefix":"10.1038","volume":"48","author":[{"given":"Elisa","family":"Pabon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-2332","authenticated-orcid":false,"given":"Ziva D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"1538_CR1","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","volume":"107","author":"AM Freeman","year":"2019","unstructured":"Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. 2019;107:696\u2013712.","journal-title":"Neurosci Biobehav Rev"},{"key":"1538_CR2","doi-asserted-by":"publisher","unstructured":"Englund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, et al. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacol. 2022. https:\/\/doi.org\/10.1038\/s41386-022-01478-z.","DOI":"10.1038\/s41386-022-01478-z"},{"key":"1538_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","volume":"269","author":"N Solowij","year":"2019","unstructured":"Solowij N, Broyd S, Greenwood L, van Hell H, Martelozzo D, Rueb K, et al. A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. 2019;269:17\u201335.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1538_CR4","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1007\/s00213-022-06248-9","volume":"239","author":"NRPW Hutten","year":"2022","unstructured":"Hutten NRPW, Arkell TR, Vinckenbosch F, Schepers J, Kevin RC, Theunissen EL, et al. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis. Psychopharmacol (Berl). 2022;239:3731\u201341.","journal-title":"Psychopharmacol (Berl)"},{"key":"1538_CR5","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.isci.2019.100794","volume":"23","author":"A Hasbi","year":"2020","unstructured":"Hasbi A, Madras BK, Bergman J, Kohut S, Lin Z, Withey SL, et al. \u0394-Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons. IScience. 2020;23:100794.","journal-title":"IScience"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01538-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01538-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01538-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T14:05:16Z","timestamp":1683122716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-023-01538-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1038\/s41386-023-01538-y","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"23 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests or disclosures with this publication. Outside of this work, ZDC reports receiving study drug from Canopy Growth Corp and True Terpenes, and study-related materials from Storz & Bickel. She served a scientific consultant for Canopy Growth Corporation in 2021 and on the scientific advisory board for FSD Pharma in 2020. ZDC\u2019s research is funded by grants from the National Institute on Drug Abuse, National Center for Complementary and Integrative Health, California Department of Cannabis Control, Center for Medicinal Cannabis Research, and the California Highway Patrol.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}